The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ORGANIZATION
ORGANIZATION
- Ishikawa Pharmacist Group Makes Direct Plea to Health Minister for Ad-Hoc Lifting of Shipment Curbs
January 19, 2024
- JPMA Calls for Setting Broad Spillover Exclusions in Market Expansion Re-Pricing
January 19, 2024
- 80-90% of Clinics in Northern Noto Not Functioning: JMA Official
January 12, 2024
- Wholesalers Ask for Prioritized Drug Supply for Disaster Areas; Emergency Dispensing Scheme Begins
January 11, 2024
- FPMAJ Stands Firmly Against Full Implementation of Off-Year Price Revision in FY2025
January 9, 2024
- Trade Groups, Academic Societies Urge Govt to Expand Coverage for CGP Testing
December 26, 2023
- Awareness Rate for Drug Lag, Loss at 17.6%, Up 5.2 Points from FY2022: JPMA Poll
December 22, 2023
- Reform Package Is “First Step” towards Global Standard, but More Work Remains: JPMA
December 22, 2023
- EFPIA Japan Names Novo’s Mejlvang as New Vice Chair
December 22, 2023
- Pharma Trade Groups Applaud FY2024 Drug Pricing Reform Outline
December 21, 2023
- JMA, JDA, JPA Call for Mitigation Measures for New LLP Coverage Rule
December 21, 2023
- Generic Use Rate Hits Record 82.2% in July-September: JGA
December 21, 2023
- JEMA Raises Alarm on Drug Loss of Complex Generics, Urge Development Incentives
December 11, 2023
- JA Survey Confirms Narrowing Down of Wholesalers by 4 Drug Makers as of April
December 8, 2023
- Gap between Poll Results and Drug Availability “Inevitable,” FPMAJ Says after JMA’s Criticism
November 22, 2023
- New Group Led by MRI to Issue Clinical Trial Policy Proposals by September 2024
November 22, 2023
- Israel-Palestine Conflict to Have Limited Impact on Japan Pharma Sector for Now: JPMA
November 17, 2023
- JPMA Gearing Up for Drug Pricing Reform Debate towards December: Exec
November 17, 2023
- Policy Veterans’ Group Renews Call for Company-Proposed Pricing, Floats Support System for Biosimilars
November 15, 2023
- PhRMA Chief Presses Japan to Cut LLP Spending, Shift Funds towards Innovation
November 15, 2023
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…